Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 2008;46:62-64; doi:10.1136/dtb.2008.07.0018
Copyright © 2008 by the BMJ Publishing Group Ltd.

What role for {blacktriangledown}tigecycline in infections?

Relevant BNF section: 5.1.3

{blacktriangledown}Tigecycline (pronounced tie-ge-sigh-cleen; Tygacil – Wyeth) is a broad-spectrum antibacterial and the first glycylcycline to be marketed in the UK. It is active against certain resistant bacteria, including meticillin-resistant Staphylococcus aureus (MRSA) and bacteria that produce extended-spectrum β-lactamase (ESBL).1,2 Tigecycline is licensed for intravenous treatment of adults with complicated skin and soft tissue infections, and complicated intra-abdominal infections.1 We review tigecycline and assess its place for these infections.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Coming soon!

The DTB archive back to 1962, volume 1, issue 1 will soon be available.